Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Jérôme Raffenne

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5344-5674; OpenAlex author ID A5032401222. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2018: 2 papers · 2019: 2 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 9

  1. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. Co-author DOI 10.1002/path.6398↗
  2. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenoc… Co-author DOI 10.1002/path.6011↗
  3. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Co-author DOI 10.1016/j.jcmgh.2021.01.008↗
  4. Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer Co-author DOI 10.1016/j.pan.2021.05.117↗
  5. Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features. Co-author DOI 10.3390/cancers13061234↗
  6. Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset. First author DOI 10.3390/cancers11010126↗
  7. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Co-author DOI 10.3390/cancers11111808↗
  8. [Molecular characterisation defines several subtypes of pancreatic ductal adenocarcinoma]. Co-author DOI 10.1016/j.bulcan.2017.11.010↗
  9. Tumor Heterogeneity in Pancreatic Adenocarcinoma. First author DOI 10.1159/000477773↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jerome F. Cros · 8 shared papers, 2018–2025 · strength 1.00
  2. Rémy Nicolle · 7 shared papers, 2019–2025 · strength 0.82
  3. Anne Couvelard Benveniste · 5 shared papers, 2018–2025 · strength 0.61
  4. Cindy Neuzillet · 4 shared papers, 2021–2025 · strength 0.53
  5. Vinciane Rebours · 3 shared papers, 2021–2025 · strength 0.44
  6. Marc Hilmi · 2 shared papers, 2022–2025 · strength 0.33
  7. Corinne Bousquet · 3 shared papers, 2021–2022 · strength 0.32
  8. Rémi Samain · 3 shared papers, 2021–2022 · strength 0.32
  9. Juan Iovanna · 2 shared papers, 2021–2025 · strength 0.32
  10. Nelson Dusetti · 2 shared papers, 2021–2025 · strength 0.32
  11. Louis de Mestier · 2 shared papers, 2019–2025 · strength 0.29
  12. Valérie Paradis · 3 shared papers, 2019–2021 · strength 0.28
  13. Magali Richard · 1 shared paper, 2025 · strength 0.21
  14. Yvan Martineau · 2 shared papers, 2021 · strength 0.20
  15. Stéphane Pyronnet · 2 shared papers, 2021 · strength 0.20
  16. Christine Jean · 2 shared papers, 2021 · strength 0.20
  17. Magali Svrcek · 2 shared papers, 2019–2021 · strength 0.18
  18. Francesco Puleo · 2 shared papers, 2019–2021 · strength 0.18
  19. Jean‐Baptiste Bachet · 2 shared papers, 2019–2021 · strength 0.18
  20. Annemilaï Tijeras‐Raballand · 1 shared paper, 2022 · strength 0.12
  21. Hemant Mahendrakumar Kocher · 1 shared paper, 2022 · strength 0.12
  22. Nicolas Poté · 1 shared paper, 2018 · strength 0.12
  23. Sauyeun Shin · 1 shared paper, 2021 · strength 0.11
  24. Jérôme Torrisani · 1 shared paper, 2021 · strength 0.10
  25. Pascal R. Hammel · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.